SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD.

Sihuan Pharmaceutical Holdings Group Ltd.

460 BMG8162K1137

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:20 2024-04-26 am EDT			5-day change	1st Jan Change
0.56 ^HKD	+3.70%		+9.80%	-13.85%

Apr. 25	Sihuan Pharma Unit Wins Bid to Supply Insulin Products to Chinese Government	MT
Mar. 29	Sihuan Pharmaceutical Narrows 2023 Loss on Absence of Asset, Investment Impairments	MT

Sihuan Pharmaceutical Holdings Group Ltd. Announces Change of Principal Place of Business in Hong Kong

June 16, 2023 at 12:00 am EDT

The board of directors of Sihuan Pharmaceutical Holdings Group Ltd. announced that the principal place of business of the company in Hong Kong has been changed to Room 4905, Office Tower, Convention Plaza, 1 Harbour Road, Wanchai, Hong Kong with effect from 16 June 2023.

Latest news about Sihuan Pharmaceutical Holdings Group Ltd.

Sihuan Pharma Unit Wins Bid to Supply Insulin Products to Chinese Government	Apr. 25	MT
Sihuan Pharmaceutical Narrows 2023 Loss on Absence of Asset, Investment Impairments	Mar. 29	MT
Sihuan Pharmaceutical Holdings Group Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Sihuan Pharmaceutical's RF Device Wins Registration Approval in China	Mar. 25	MT
Sihuan Pharmaceutical Holdings Unit Forms Consortium for Ji Yao Restructuring	Feb. 08	MT
China Approves Drug Registration for Sihuan Pharmaceutical Unit's Type 2 Diabetes Drug	Jan. 22	MT
Sihuan Pharmaceutical Holdings Group Ltd. Receives Registration Approval from National Medical Products Administration for Proline Janagliflozin Tablets	Jan. 22	CI
China Includes Four Injectables by Sihuan Pharma Associate in Drug Reimbursement List; Shares Rise 3%	Jan. 10	MT
China Grants Registration Approval to Sihuan Pharmaceutical's Insulin Products	Jan. 08	MT
Sihuan Pharmaceutical Holdings Group Ltd. Obtains Drug Registration Approval from the National Medical Products Administration of the People's Republic of China for the Treatment of Diabetes	Jan. 07	CI
China's Medical Products Administrator Approves Sihuan Pharma Unit's Diabetes Drug	23-10-24	MT
National Medical Products Administration Approves IND Application of Insulin Degludec and Liraglutide Injection, Developed by Huisheng Biopharmaceutical	23-10-24	CI
China Accepts New Drug Application of Sihuan Pharmaceutical Subsidiary's Breast Cancer Treatment	23-10-16	MT
China Accepts New Drug Application for Sihuan Pharmaceutical Unit's Breast Cancer Tablets	23-09-04	MT
Sihuan Pharmaceutical Swings to H1 Loss	23-08-29	MT
Sihuan Pharmaceutical Holdings Group Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-29	CI
Sihuan Pharmaceutical's Revenue to Drop 30% in H1	23-08-03	MT
Sihuan Pharmaceutical Holdings Group Ltd. Provides Unaudited Consolidated Guidance for the Six Months Ended 30 June 2023	23-08-02	CI
China Approves Sihuan Unit's Clinical Trial for Diabetes Injections; Shares Fall 3%	23-07-06	MT
Sihuan Pharma to Conduct Clinical Trials of Diabetes Injection	23-07-04	MT
Sihuan Pharma Unit Gets Nod to Test Diabetes Drug	23-07-04	MT
Sihuan Pharmaceutical Holdings Group Ltd. Announces Huisheng Biopharmaceutical's Drug Semaglutide Injection Obtained Approval for Clinical Trial	23-07-04	CI
China Approves Sihuan Pharmaceutical Unit's Phase 2 Trial for Metastatic Prostate Cancer Treatment	23-07-03	MT
Sihuan Pharmaceutical Holdings Group Ltd. Announces Approval of Phase II Clinical Trial Application of Birociclib by the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China	23-07-03	CI
Sihuan Pharma Unit Gets Nod for Marketing of Ulcer Drug	23-06-26	MT

Chart Sihuan Pharmaceutical Holdings Group Ltd.

Duration

Period

Chart Sihuan Pharmaceutical Holdings Group Ltd.

More charts

Company Profile

Sihuan Pharmaceutical Holdings Group Ltd is a holding company mainly engaged in pharmaceutical manufacturing business. The Company operates three segments. Medical Aesthetic Products segment includes the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skin care and others to provide non- or minimally invasive medical aesthetics comprehensive solutions. Innovative Medicine and Other Medicine segment is engaged in the research and development of innovative drugs in the fields of digestion, oncology, non-alcoholic hepatitis, diabetes and complications. The Company also operates Generic Medicine segment.

Sector

Pharmaceuticals

Calendar

2024-08-26 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.56

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD.	-13.85%	664M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals